3q fy2012(fiscal year ending march 31, … development, including completion of c linical trials;...
TRANSCRIPT
3Q FY2012(Fiscal Year Ending March 31, 2013)
Financial Results Presentation
February 1, 2013
Eisai Co., Ltd.
2
Safe Harbor Statement
• Materials and information provided during this presentation may contain so-called “forward-looking statements.” These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.
• Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy; regulatory agency’s examination period, obtaining regulatory approvals; domestic and foreign healthcare reforms; trends toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.
• Also, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance.
• The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
• This English presentation was translated from the original Japanese version. In the event of any inconsistency between the statements in the two versions, the statements in the Japanese version shall prevail.
3
April – December 2011 April – December 2012
Results % Results % YOY
Net Sales 504.8 100.0 431.6 100.0 85
Cost of Sales 129.3 25.6 128.1 29.7 99
Gross Profit 375.5 74.4 303.4 70.3 81
R&D Expenses 93.9 18.6 87.2 20.2 93
SG&A Expenses 199.4 39.5 162.0 37.5 81
Operating Income 82.2 16.3 54.1 12.5 66
Ordinary Income 77.9 15.4 50.2 11.6 64
Net Income 49.2 9.7 34.0 7.9 69
88. ….a
(Billion yen, %)
3Q FY2012 Consolidated Financial Results
Cash income is the total amount of cash available for investments for growth, business development, dividend payment, and repayment of borrowings, etc.Cash income = Net income + Depreciation of PP&E and Amortization of intangible assets + In-process R&D + Amortization of goodwill + Loss on impairment (including loss on devaluation of investment securities)3Q FY2012 average exchange rates: U.S.$ = 80.0 yen (YOY1.2%), Euro = 102.2 yen (YOY –7.6%), GBP = 127.1 yen (YOY 0.3%)
Cash Income 85.7 72.9 85
4
Sales of Oncology Franchise Products Franchise transformation progresses as planned in the Plan “HAYABUSA”
Oncology-related products grew 107% accounting for 17% of net sales Oncology-related products sales forecast is 100 billion yen in FY2012
April-December
2011
April-December2012
Results Results YOY
Halaven 10.9 16.4 151[152]
Aloxi 25.9 27.1 105[104]
Dacogen 12.8 13.5 106[104]
Fragmin 10.8 7.8 72[71]
Treakisym/Symbenda 2.5 2.7
110[110]
Others 6.3 6.3 100
Oncology-related products
Total69.1 73.8 107
[106]
2011年度上期 2012年度上期 計画「はやぶさ」
2015年度
26% 27%21%
4% 5%6%
22% 22%
12%
2% 3%
9%
32% 26%29%
14% 17%22%
がん
脳神経
てんかん
消化器・肝臓
免疫/アレルギー
他ブランド
(Billion yen, %)
[ ] based on local currencyFY2011 3Q Plan “HAYABUSA”
FY2015FY2012 3Q
Oncology
Neuroscience
GI/Liver
Other brandedproducts
Immunology/Allergy
Epilepsy
5
Sales of Aricept and Pariet/AcipHex
April-December
2011
April – December2012
Results Results YOY
East Asia*1
Japan95.691.2
60.656.0
6361
Americas*2
[$ million]9.4
[119] 9.3
[117]99
[98]
EMEA*3 17.1 2.3 13[15]
Indo-Pacific*4 1.3 1.3 99[101]
Total 123.4 73.6 60[60]
April-December
2011
April – December2012
Results Results YOY
East Asia*1
Japan49.947.8
40.638.6
8181
Americas*2
[$ million]42.9
[543]37.8
[473]88
[87]
EMEA*3 4.1 2.4 59[63]
Indo-Pacific*4 1.3 1.2 96[98]
Total 98.2 82.1 84[83]
*1 Japan, China, South Korea, Taiwan and Hong Kong*2 North America, Central and South America *3 Europe, Middle East and Africa*4 South Asia, ASEAN and Oceania
AcipHex: received additional six months exclusivity in the U.S. until November 8, 2013
(Billion yen, %)Aricept Pariet/AcipHex (Billion yen, %)
[ ] based on local currency [ ] based on local currency
April - December2011
April – December2012
Sales % Sales % YOY
East AsiaJapanChina
315.7294.313.0
62.558.3
2.6
274.6250.015.8
63.657.9
3.7
8785
122Americas[$ million]
119.8[1,516] 23.7 114.5
[1,431] 26.5 96[94]
EMEA 34.0 6.7 18.9 4.4 55[59]
Indo-Pacific 5.1 1.0 5.1 1.2 100[102]
Reporting Segment Total 474.6 94.0 413.1 95.7 87
[87]
Others 30.2 6.0 18.5 4.3 61
Consolidated Sales 504.8 100.0 431.6 100.00 85
[86]
6
Sales by Segment Regional transformation progresses as planned in the Plan “HAYABUSA”
Pharmaceuticals Businesses of East Asia, Americas, EMEA and Indo-Pacific. Segment profit from Americas Pharmaceuticals Business in local currency was calculated based on average exchange rate.
(Billion yen, %)
[ ] based on local currency FY2011 3Q Plan “HAYABUSA”FY2015
FY2012 3Q
6% 4% 3%1% 1% 3%
7%4% 7%
24%27% 24%
63% 64% 63%
イースト アジア
アメリカス
EMEA
Indo-Pacific
その他事業
East Asia
EMEA
Others
Americas
Indo-Pacific
7
Profit by Segment
April – December 2011 April – December 2012
SegmentProfit
%ProfitRatio
SegmentProfit
%ProfitRatio
YOYDifference
from previous
year
East AsiaJapan
136.2131.9
74.772.4
43.144.8
111.0106.2
74.871.5
40.442.5
8281
(25.1)(25.7)
Americas[$ million]
24.7[312]
13.5 20.6 25.7[321] 17.3 22.4
104[103]
1.0[9]
EMEA 5.2 2.9 15.4 1.3 0.9 6.9 25 (3.9)
Indo-Pacific 1.4 0.7 26.5 1.2 0.8 24.0 90 (0.1)
Reporting Segment Total 167.4 91.9 35.3 139.3 93.8 33.7 83 (28.2)
Others 14.8 8.1 49.1 9.2 6.2 49.6 62 (5.6)
R&D expenses & Non-allocated SG&A expenses
(100.0) (94.3) 94 5.7
Consolidated Operating Profit 82.2 16.3 54.1 12.5 66 (28.1)
Pharmaceuticals Businesses of East Asia, Americas, EMEA and Indo-Pacific.Segment profit from Americas Pharmaceuticals Business in local currency was calculated based on average exchange rate.
(Billion yen, %)
FY2011 FY2012Results % Forecast % YOY
Net Sales 648.0 100.0 573.5 100.0 89Cost of Sales 173.4 26.8 172.4 30.1 99
Gross Profit 474.6 73.2 401.1 69.9 85R&D Expenses 125.1 19.3 118.0 20.6 94SG&A Expenses 253.7 39.1 211.6 36.9 83
Operating Income 95.7 14.8 71.5 12.5 75Ordinary Income 90.0 13.9 66.5 11.6 74Net Income 58.5 9.0 47.0 8.2 80
EPS (yen) 205.3 164.9ROE (%) 14.3 11.0DOE (%) 10.4 10.0Cash Income 107.7 100.0Dividends (yen) 150 150
Forecast for FY2012 Consolidated Financial Results Maintain 150 yen dividend for FY2012 based on the policy
to focus on shareholder value
Cash income is the total amount of cash available for investments for growth, business development, dividend payment, and repayment of borrowings, etc.Cash income = Net income + Depreciation of PP&E and Amortization of intangible assets + In-process R&D + Amortization of goodwill + Loss on impairment (including loss on devaluation of investment securities)FY2011 average exchange rate: U.S. $ = 79.08 yen, Euro = 108.97 yen, GBP = 126.22 yen Estimated exchange rates for FY2012: U.S. $ = 88 yen, Euro = 117 yen, GBP = 142 yenForecast for FY2012 was revised in consolidated financial report for the third quarter of fiscal 2012 (Fiscal year ending March 31, 2013, Japan GAAP)
8
(Billion yen, %)
Aricept in JapanStarted independent promotion on January 1, 2013
2H FY2012 Market Status Competitive landscape of generic and other branded products is stabilizing* Sales forecast in FY2012: 75 billion yen
Further patient contribution as a pioneer in AD therapeutic area Initiated new DTC for disease awareness on January 9
Aricept Anshin (Reliable) Support Center
Aricept is the only Acetylcholinesterase inhibitorindicated for severe AD
9
Improvement in adherence rate
Awareness for significance of treating severe AD (increase in 10mg tablets ratio)
Promote diagnosis for potential patients
* (Internal estimates) Aricept share in donepezil: 71% in October, 73% in November, 71% in December, Aricept share in branded AD treatments: 64% in October, 67% in November, 64% in December
10
Growth Drivers in Rising East Asia
(Billion yen)
(Billion yen, %)
Growth driver for the next generation 3Q FY2011 3Q FY2012 YOY
Halaven 1.8 4.1 226
Treakisym 2.5 2.6 108
Humira 15.4 18.1 118
Lyrica(alliance revenue) 8.4 10.3 123
Lunesta, Careram,Lipacreon and Fostoin 0.1 2.2 -
Total 28.2 37.4 133
Aiming for20 billion yen sales
respectively in FY2012
3Q FY2011 3Q FY2012 YOY
China Business 13.0 15.8 122
Generic Business 10.1 13.5 134
<Business>
<New Products in Japan>
(Billion yen, %)
3Q FY2011 3Q FY2012
11
Phase III Study (Study 301) Results of Halaven Versus Capecitabine in Locally Advanced or Metastatic Breast Cancer
11
Study 301 resultsPresented at San Antonio Breast Cancer Symposium
Oral presentation of Study 301 at SABCS on December 7, 2012
The study demonstrated a trend that favored improved OS with Halaven compared with capecitabine, which was clinically meaningful
*1: OS: overall survival; PFS: progression-free survival *2: Exploratory analyses, including one analysis based on the expression status of human epidermal growth factor receptors (HER2s), which was a pre-specified stratification factor in the study protocol, and other analyses based on hormone receptor expression status, which were not pre-specified stratification factors in the study *3: Triple negative breast cancer refers to cancer type which does not express estrogen, progesterone or HER2 *4: Nominal p-value
The study did not meet the pre-specified criteria (p-value) for OS*1 and PFS*1 with statistical
significance; however, it showed a trend toward improved OS for certain patients who received
Halaven compared with capecitabine
PatientsMedian OS
Hazard ratio p-valueHalaven capecitabine
All patients 15.9 months 14.5 months 0.879 0.056HER2-negative*2 15.9 months 13.5 months 0.838 0.030*4
Triple negative*2,3 14.4 months 9.4 months 0.702 0.006*4
12
Phase III Study (Study 301) Results of Halaven Versus Capecitabine in Locally Advanced or Metastatic Breast Cancer
Eisai global response
12
Japan Hosted a Halaven educational session for
Japanese KOLs and others at SABCS Presented details of Study 301 and
discussed sub-group analyses, chemotherapy orders and others
MRs are communicating the study result to doctors by using iPads in Japan
EU Planning to submit for earlier lines of
treatment in locally advanced or metastatic breast cancer at the end of March 2013
U.S. Appropriately respond to study results
inquiries
Product Creation Pursue evidence in clinical studies
in earlier lines of treatment Target specific patient group in neo adjuvant and
adjuvant treatments Strategic use of biomarker in clinical study for
first-line treatment
Better understand Halaven’s mechanism to extend OS in non-clinical study Propose new mechanism that can potentially
rationalize Halaven’s mechanism to extend OS
Publication Preparing for submission of Study
301 for publication
Guidelines Closely monitor placement of Study
301 results on the guidelines of academic conferences and medical institutions
13
Toward Maximizing The Product Value of Halaven
Non-small-cell lung cancer (NSCLC) (late-line): In Phase III study (Study 302), LPI achieved in November 2012,16 months ahead of planned schedule;aim for global submissions in FY2013
Soft-tissue sarcoma: Phase III study (Study 309) is steadily ongoing; Data Monitoring Committee recommended to continue without modification
Steady progress in clinical studiesfor potential indication/formulation expansion
NSCLC(Late line)
Submission Schedule
Soft-tissuesarcoma
Liposomal formulation: First patient initiated treatment in December 2012 in Phase l study (Study 112); the study is ongoing steadily
MBC(earlier lines)
(EU)
Maximize potential by continuing to explore Halavenin over 40 internal and external clinical studies
FY2013 FY2014FY2012
1414
Fycompa Contributions to Patients with EpilepsyFirst-in-class non-competitive AMPA receptor antagonist
EU: Steadily progressing with additional launches Launched in Sweden in December 2012
and in Norway in January 2013; launched in 6 countries including U.K, Germany, Austria, and Denmark
Scottish Medicines Consortium approved Fycompa for national health service usein Scotland in December;first global health technology assessment (HTA)
HTA is ongoing in Germany; final decision on the additional benefit evaluation will be available in March
Approved in Switzerland in December
Preparing for launch in the U.S. Plan launch in 1Q FY2013
following final DEA* scheduling
* Drug Enforcement Administration
500
1000
1500
2000
GermanyUK
Reference: Based on In Market sales data from IMS in U.K. & Germany
Cumulative number of patients in Germany and U.K.
15
Lennox-Gastaut Syndrome*2designated as Orphan
drug in the U.S.Phase III in preparation
Partial Onset Seizures (Launch, submission)
Toward Maximizing The Product Value of Fycompa
Partial Onset Seizures
Primary Generalized Tonic-Clonic Seizures*2
(PGTC)
Partial Onset Seizures Pediatric*2
EU: launched U.S.: preparing for launchJapan: target submission
in FY2014Phase III
U.S. and EU: target submissions in FY2013
Phase II
*1 Source: World Health Organization (WHO)*2 Potential Indications subject to approval(s)
FY2014FY2012 FY2013
EU
U.S., EU
U.S.
PGTC (Submission)
Japan, Korea
Japan
(launched) (launch plan) (submission plan)
Seek contribution to 50 million*1patients globally
Progress in Investigational Antibody Drug Development at Morphotek Product Creation Unit
Farletuzumab(MORAb-003)
MORAb-004Three different Phase II studies are underway, including one investigating biomarkers to identify potential companion diagnostics agents
Investigational humanized monoclonal antibody
developed by Morphotek, targeting tumor endothelial
marker-1 (TEM1), or endosialin
Result of Phase III study for platinum-sensitive ovarian cancer Number of study patients: 1,100 cases (599 events) In this study, farletuzumab, in combination with carboplatin and a taxane, failed to
show the pre-defined statistically significant difference in PFS, primary endpoint, in comparison with placebo-treated group. A post hoc exploratory analysis showed a trend toward improved PFS in some patent subsets and further analysis is ongoing. Future development strategy is now being considered at meetings with external experts and consultations with the regulatory authority
Interim analysis of OS, secondary endpoint, is planned The preliminary safety analysis indicated that the
most commonly reported adverse events were those known to be associated with study chemotherapeutic agents. Also some immune-mediatedevents were observed with farletuzumab
NSCLC
Phase II study for patients with overexpressed folate receptoralpha is ongoing; patient enrollment is completed
First-in-class investigational humanized monoclonal antibody developed by
Morphotek, targeting folate receptor alpha (FRA)
Diagnostic kit to detectFRA overexpression
Planning to developas companion diagnostic kit for Phase III study for NSCLC
Melanoma: Protocol-defined number of patients have enrolled for Phase IIa study
Colorectal cancer: Phase II study is ongoing with interim analysis planned in FY2012; planning to complete the study in FY2013
Sarcoma: Phase II study is ongoing16
Fibroblast
Endosialin
Cancer cellPericytes
17
Lenvatinib (E7080)
Steady Progress of Investigational Lenvatinib
In-house developed, oral, molecular-targeting agent with a unique inhibitory profile of receptor tyrosine kinases, mechanism of action may occur from both inhibition of angiogenesis and tumor proliferation
<Target indications>Thyroid cancer, HCC,
RCC, NSCLC, endometrial cancer, melanoma, glioma,
etc.
Differentiated thyroid cancer: Planning submission in FY2013Global Phase III study enrollment is completed and trial is ongoing
HCCGlobal Phase III study started
NSCLC Phase II study started in the U.S., Europe, Japan and Asia with patients with RET chromosomal translocation
Clinical studies for endometrial cancer (Phase II), melanoma (Phase II), glioma (Phase II), RCC (Phase Ib/II), and solid cancer in combination with Golvatinib (Phase I/II) are progressing steadily
Chart: Created based on Nature Biotechnology 2005;23(3)
• Detect chromosomal translocation using deep sequencing technology
• Initiated investigation to develop companion diagnostics agents
18
AcipHexProton pump inhibitor, approved in more than
90 countries worldwide*
with over 120 billion yen of sales
AcipHex (U.S.) Seeking approval for additional indication to cover a broader range of GERD
patients from one-year-old to adult patients NDA for pediatric indication was filed and additional exclusivity was granted
Pediatric NDA was accepted for priority review on September 27, 2012 Expected FDA Action Date: March 27, 2013
AcipHex satisfied FDA pediatric written request requirements and received additional six months pediatric exclusivity until November 8, 2013
Sales in FY2011 in the U.S.: $707 million
Approved indications in the U.S. (as of January 2013):Treatment of erosive/ulcerative gastroesophageal reflux disease (GERD) in adult patients, maintenance of healed erosive/ulcerative GERD, treatment of symptomatic GERD, healing of duodenal ulcers, H. pylori eradication in duodenal ulcers in combination with other agents
* including sales territory of Johnson & Johnson
Pediatric formulation
Expansion of Strategic AllianceEarlier maximization of pipeline
にすと
Enable early innovative and new drug creation through R&D collaboration
19
Lead to strategic expansion in indication of
Eisai’s pipelinewith hope for POC
achievement
Establish effective treatment for lymphoma patients who have genetic mutation of EZH2 in the active cancer
epigenetic field
Santen Pharmaceutical Co., Ltd.
Epizyme, Inc.Roche Molecular Systems Inc. Quintiles
Phase II studies of Eisai six compounds
(Halaven, lenvatinib, etc.)are ongoing steadily
Value maximization of Eisai’s pipeline through expansion
into ophthalmology field
Collaborate on development of a companion diagnostic to identify genetic mutation
of EZH2, histone methyltransferases (HMTs)
Eisai grants Santen rights of evaluation for
Eisai-owned compounds in the field
of ophthalmology
Expansion in therapeutic area Focus in disease Expansion in indication
Abundant Growth Drivers in Product PortfolioGlobal launches in succession increase corporate value
20
New products already launched Halaven Approved in 44 countries and launched in the U.S., EU, Japan, and others
Submission for earlier lines of treatment in locally advanced or metastatic breastcancer is planned in EU by the end of FY2012
Lunesta Insomnia treatment that improves difficulty with falling asleep and staying asleepLaunched in Japan in April 2012; restriction on administration period to be lifted in May 2013
Fycompa Approved in 31 countries, and launched in EU in September 2012 Careram A novel disease-modifying anti-rheumatic drug that inhibits production of
inflammatory cytokine and immunoglobulin; launched in September 2012Gliadel World’s only implant in the brain, sustained release formulation for brain tumor
(malignant glioma); launched in Japan in January 2013
New products soon-to-be launchedBELVIQ Approved in the U.S. in June 2012; expected to be launched in 4Q FY2012
Fycompa Expected to be launched in the U.S. in 1Q FY2013
Actonel Once-monthly formulation for the treatment of osteoporosis Approved in Japan in December 2012; expected to be launched in February 2013
Pricing Will Reflect BELVIQ’s Unique Value Proposition
Safety, efficacy, and tolerability profile that allows for broad distribution with approved patient population upon product launch
Novel mechanism of action and patented new chemical entity serotonin (5-HT2c) receptor agonist
Convenient and simple product dosing
Ready for FY2012 Launch: BELVIQUnique value proposition and strong clinical profile
Chronic Weight Management Rx Market-Leading Potential
Pivotal study published in prestigious New England Journal of Medicine Successful study in at-risk patient population
BLOOM-DM results in overweight and obese diabetic patients included in product label
Statistically significant effect on glycemic control in diabetic patients (HbA1c and fasting plasma glucose)
Sustained efficacy in patients who achieve 5% or more weight loss benefit within 12 weeks of treatment
Well characterized safety profile for the appropriate patient population22
23
Prior experience in GERD market positions Eisai for effective execution in the chronic weight management market
Substantial patient and physician overlap for obesity and GERD
Prior contracting experience with payors on broad market productAcipHex experience provides us with unique capabilities that directly relate to
chronic weight management market
a
Experience in establishing underserved prescription markets
Seeking 40% coverage of commercial lives*1 within first
year of launchSeeking >50% coverage of
commercial lives
Launch year 3 and beyondSeeking 70% coverage of
commercial lives plus access to public lives*2 through removal of
government restrictions
Launch year 1 Launch year 2
Leveraging Commercial Experience
*1: Commercial lives includes individuals who privately purchase medical insurance or receive it through workplace benefits*2: Public lives includes individuals who receive medical insurance coverage through government-sponsored programs
2525
Performance of East Asia Pharmaceuticals Business
April – December 2011 April – December 2012
Results % Results % YOY
Sales 315.7 100.0 274.6 100.0 87
Aricept 95.6 30.3 60.6 22.1 63
Pariet 49.9 15.8 40.6 14.8 81
Methycobal 29.3 9.3 27.1 9.9 92
HUMIRA 18.0 5.7 21.6 7.9 120
Stronger Neo-Minophagen C/ Glycyron Tablets 6.1 1.9 6.4 2.3 105
Segment Profit 136.2 43.1 111.0 40.4 82
(Billion yen, %)
26
Performance of East Asia Pharmaceuticals Business
April – December 2011 April – December 2012Results % Results % YOY
Sales 1,055 100.0 1,247 100.0 118Methycobal 465 44.1 534 42.8 115Stronger Neo-Minophagen C/ Glycyron Tablets
226 21.4 271 21.7 120
Aricept 106 10.0 127 10.2 121Pariet 67 6.4 82 6.6 121
April – December 2011 April – December 2012Results % Results % YOY
Sales 294.3 100.0 250.0 100.0 85Prescription 263.9 89.7 216.4 86.6 82Aricept 91.2 31.0 56.0 22.4 61Pariet 47.8 16.2 38.6 15.4 81Methycobal 23.4 8.0 20.1 8.0 86HUMIRA 15.4 5.2 18.1 7.2 118Actonel 8.8 3.0 6.9 2.8 79OTC 15.9 5.4 15.8 6.3 99Generics 10.1 3.4 13.5 5.4 134Diagnostics 4.4 1.5 4.3 1.7 97Segment Profit 131.9 44.8 106.2 42.5 81
<Japan>
<China>
(Billion yen, %)
(MM RMB, %)
27
Performance of Americas Pharmaceuticals Business
April – December 2011 April – December 2012
Results % Results % YOY
Sales 119.8 100.0 114.5 100.0 96Aricept 9.4 7.9 9.3 8.2 99AcipHex 42.9 35.8 37.8 33.0 88
Halaven 7.9 6.6 8.5 7.5 109Aloxi 25.9 21.6 27.1 23.7 105Dacogen 12.8 10.7 13.5 11.8 106
Total MGI 40.5 33.8 42.7 37.3 105
Fragmin 10.8 9.0 7.8 6.8 72
Total oncology-related products 62.3 52.0 61.7 53.9 99
Segment Profit 24.7 20.6 25.7 22.4 104
(Billion yen, %)
2828
Performance of Americas Pharmaceuticals Business
April – December 2011 April – December 2012
Results % Results % YOY
Sales 1,516 100.0 1,428 100.0 94Aricept 119 7.9 117* 8.2 98AcipHex 543 35.8 473 33.1 87
Halaven 99 6.6 106 7.4 107Aloxi 327 21.6 339 23.8 104Dacogen 162 10.7 169 11.8 104
Total MGI 513 33.8 534 37.4 104
Fragmin 137 9.0 97 6.8 71
Total oncology-related products 788 52.0 770 53.9 98
* Including Aricept 23mg sales of $56M
<U.S.A> [$ million, %]
29
Performance of EMEA and Indo-Pacific Pharmaceuticals Business
April – December 2011 April – December 2012
Results % Results % YOY
Sales 34.0 100.0 18.9 100.0 55 [59]
Aricept 17.1 50.2 2.3 12.2 13 [15]
Pariet 4.1 12.0 2.4 12.8 59 [63]
Zonegran 3.4 10.1 3.4 18.0 99 [105]
Halaven 1.2 3.4 3.6 19.3 316 [336]
Segment Profit 5.2 15.4 1.3 6.9 25 [38]
April – December 2011 April – December 2012
Results % Results % YOY
Sales 5.1 100.0 5.1 100.0 100 [102]
Aricept 1.3 25.5 1.3 25.2 99 [101]
Pariet 1.3 25.2 1.2 24.1 96 [98]
Segment Profit 1.4 26.5 1.2 24.0 90 [91]
<Indo-Pacific>
<EMEA>
[ ] based on local currency
(Billion yen, %)
(Billion yen, %)
[ ] based on local currency